Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR) has announced participation in two upcoming virtual investor conferences. The Wells Fargo Virtual Healthcare Conference is scheduled for September 9, 2021, at 4:00 PM ET, featuring CEO John Fowler and CMO Noreen Roth Henig. The H. C. Wainwright 23rd Annual Global Investment Conference will occur on September 13, 2021, at 7:00 AM ET, with John Fowler presenting. Webcasts can be accessed on the company’s website and will be archived for 90 days.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in the following upcoming virtual investor conferences:

Wells Fargo Virtual Healthcare Conference
Thursday, September 9, 2021, 4:00 PM ET
Presenter: John Fowler, Chief Executive Officer, and Noreen Roth Henig, M.D., Chief Medical Officer

H. C. Wainwright 23rd Annual Global Investment Conference
Monday, September 13, 2021, 7:00 AM ET
Presenter: John Fowler, Chief Executive Officer

A webcast of both presentations may be accessed at the “Events & Presentations” section of Kezar’s website at https://www.kezarlifesciences.com/investors/news-events/ir-calendar. Kezar Life Sciences will maintain an archived replay of the webcasts on its website for 90 days after the conferences.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An IND submission for KZR-261 in solid tumors was filed in August 2021, and Kezar plans to initiate an open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005262/en/

Argot Partners

Kimberly Minarovich

(212)-600-1902

kezar@argotpartners.com

 

Source: Kezar Life Sciences, Inc.

FAQ

When is Kezar Life Sciences participating in the Wells Fargo Virtual Healthcare Conference?

Kezar Life Sciences will participate in the Wells Fargo Virtual Healthcare Conference on September 9, 2021, at 4:00 PM ET.

Who will present at the H. C. Wainwright 23rd Annual Global Investment Conference?

John Fowler, CEO of Kezar Life Sciences, will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET.

How can I access the webcasts from Kezar Life Sciences' investor conferences?

Webcasts from Kezar Life Sciences' investor conferences can be accessed in the 'Events & Presentations' section of their website.

What is the lead development candidate of Kezar Life Sciences?

Kezar Life Sciences' lead development candidate is KZR-616, a selective immunoproteasome inhibitor currently in Phase 2 trials.

What is KZR-261 being developed for?

KZR-261 is being developed as an anti-cancer clinical candidate, targeting the Sec61 translocon and the protein secretion pathway.